RT Journal Article
SR Electronic
T1 Global projections of lives saved from COVID-19 with universal mask use
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20209510
DO 10.1101/2020.10.08.20209510
A1 Gakidou, Emmanuela
A1 Pigott, David M.
A1 Troeger, Christopher E.
A1 Hulland, Erin N.
A1 Reiner, Robert C.
A1 Adolph, Christopher
A1 Aravkin, Aleksandr Y.
A1 Bachmeier, Steven D.
A1 Bang-Jensen, Bree
A1 Barber, Ryan M.
A1 Bisignano, Catherine
A1 Bloom, Sabina
A1 Carter, Austin
A1 Castro, Emma
A1 Chakrabarti, Suman
A1 Chattopadhyay, Jhilik
A1 Chen, Christine
A1 Cogen, Rebecca M.
A1 Collins, James K.
A1 Combs, Emily
A1 Cormier, Natalie Maria
A1 Dai, Xiaochen
A1 Dangel, William James
A1 Deen, Amanda
A1 Ewald, Samuel B.
A1 Flaxman, Abraham D.
A1 Fullman, Nancy
A1 Guo, Gaorui
A1 Hackman, Kathryn
A1 He, Jiawei
A1 Henry, Nathaniel J.
A1 Johanns, Casey
A1 Larson, Samantha Leigh
A1 Lazzar-Atwood, Alice
A1 LeGrand, Kate E.
A1 Lescinsky, Haley
A1 Lim, Stephen S.
A1 Linebarger, Emily
A1 Lozano, Rafael
A1 Ma, Rui
A1 Magistro, Beatrice
A1 Månsson, Johan C.
A1 Marczak, Laurie B.
A1 Miller-Petrie, Molly K.
A1 Mokdad, Ali H.
A1 Mooney, Meghan D.
A1 Odell, Christopher M.
A1 O’Halloran, James K.
A1 Ostroff, Samuel M.
A1 Pasovic, Maja
A1 Patel, Disha J.
A1 Penberthy, Louise
A1 Ramshaw, Rebecca E.
A1 Roth, Gregory A.
A1 Shaw, David H.
A1 Sheena, Brittney S.
A1 Sholokhov, Aleksei
A1 Sorensen, Reed J. D.
A1 Sparks, Gianna
A1 Spurlock, Emma Elizabeth
A1 Subart, Michelle L.
A1 Walker, Ally
A1 Watson, Alexandrea
A1 Welgan, Catherine A.
A1 Wiens, Kirsten E.
A1 Woyczynski, Lauren
A1 Xu, Liming
A1 Hay, Simon I.
A1 Brauer, Michael
A1 Vos, Theo
A1 Murray, Christopher J. L.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/18/2020.10.08.20209510.abstract
AB BACKGROUND Social distancing mandates (SDM) have reduced health impacts from COVID-19 but also resulted in economic downturns that have led many nations to relax SDM. Until deployment of an efficacious and equitable vaccine, intervention options to reduce COVID-19 mortality and minimize restrictive SDM are sought by society.METHODS A susceptible-exposed-infectious-recovered (SEIR) deterministic transmission model was parameterized with data on reported deaths, cases, and select covariates to predict infections and deaths from COVID-19 through March 01, 2021. We explore three scenarios: a “non-adaptive” scenario where neither mask use or SDM adapt to changing conditions, a “reference” where current national levels of mask use are maintained and SDM reintroduced when deaths rise, and an increase in mask use to 95% coverage levels (“universal mask”). We reviewed published studies to set priors on the magnitude of reduction in transmission through increasing mask use.RESULTS Mask use was estimated at 59.0% of people globally on October 19, 2020. Universal mask use could avert 733,310 deaths (95% UI 385,981 to 1,107,759) between October 27, 2020 and March 01, 2021, the difference between the predicted 2.95 million deaths (95% UI 2.70 to 3.35) in the reference scenario and 2.22 million deaths (95% UI 2.00 to 2.45) in the universal mask scenario over this time period.CONCLUSIONS The cumulative toll of the COVID-19 pandemic could be substantially reduced by the universal adoption of masks before the availability of a vaccine. This low-cost, low-barrier policy, whether customary or mandated, has enormous health benefits with presumed marginal economic costs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report, or decision to publish. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We only use data collected by other entities.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available to researchers and where not freely available, information on how to access the data is provided.